Source comparison
Best Thymosin Alpha-1 Dosage for Chronic Fatigue: Protocol Comparison
Hepatitis B Antiviral (Standard) 0.9mg Twice weekly 24–52 weeks HBV DNA viral load suppression Inadequate for CFS/ME. Targets viral replication, not immune restoration. Produces partial TLR9 activation without sustained cytokine shift. Chronic Fatigue Immune R
This comparison does not assign a generated winner or score.
- Hepatitis B Antiviral (Standard)
- 0.9mg
- Twice weekly
- 24–52 weeks
- HBV DNA viral load suppression
- Inadequate for CFS/ME. Targets viral replication, not immune restoration. Produces partial TLR9 activation without sustained cytokine shift.
- Chronic Fatigue Immune Restoration
- 1.6mg
- 12–16 weeks
- CD4/CD8 ratio, NK cell cytotoxicity, Th1 cytokine levels
- Evidence-based protocol for CFS/ME. Restores thymic output and cellular immunity. Requires baseline and follow-up immune markers to confirm response.
- Cancer Immunotherapy Adjunct
- 3.2mg
- 8–12 weeks
- Dendritic cell maturation, tumor antigen presentation
- Higher dose carries cytokine release risk. Not recommended for chronic fatigue without oncology indication.
- Low-Dose Maintenance (Post-Recovery)
- Once weekly
- Ongoing
- Sustained CD4/CD8 ratio stability
- Unproven in chronic fatigue. No published data on maintenance dosing after initial restoration.